MedTrace Logo

Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia

NCT02440178 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-11-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether prophylaxis with micafungin is effective in the induction chemotherapy for newly diagnosed acute leukemia patients.

Conditions

Interventions

DRUG

Micafungin

Sponsors & Collaborators

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Youngil Koh, Dr. · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-19
Primary Completion
2017-06-01
Completion
2017-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02440178 on ClinicalTrials.gov